Claims for Patent: 7,999,072

Summary for Patent: 7,999,072

Title:	Mutated netrin-4, fragments thereof and their use as medicines
Abstract:	Described is use of a netrin selected among netrin-4, mutated netrin-4, netrin-1, netrin G1 or netrin-3, or one of their fragments or a nucleotide sequence encoding one of the netrins or one of the fragments, or an anti-idiotypic antibody of one of the netrins or of one of the fragments, or of a Fab fragment of the anti-idiotypic antibodies, for preparing a medicine for preventing or treating tumoral or non-tumoral pathologies.
Inventor(s):	Plouet; Jean (Paris, FR), Alemany; Monica (Paris, FR)
Assignee:	Centre National de la Recherche Scientifique (CNRS) (Paris, FR) IVS Institut des Vaisseaux et du Sang (Paris, FR)
Application Number:	11/791,274
Patent Claims:	1. An isolated protein comprising one of the following sequences: SEQ ID NO: 522 or SEQ ID NO: 524. 2. An isolated nucleic acid comprising the nucleotide sequence SEQ ID NO: 521, or the nucleotide sequence SEQ ID NO: 523. 3. A recombinant vector, selected from the group consisting of plasmid, cosmid, phage and virus DNA, comprising the nucleotide sequence SEQ ID NO: 521, or the nucleotide sequence SEQ ID NO: 523, and the elements necessary for expression in a host cell of polypeptides encoded by said nucleotide sequences. 4. A host isolated cell selected from the group consisting of bacteria, viruses, yeasts, fungi, plants and mammal cells, said host cell being transformed by a recombinant vector comprising the nucleotide sequence SEQ ID NO: 521, or the nucleotide sequence SEQ ID NO: 523, and the elements necessary for expression in said a host cell of polypeptides encoded by said nucleotide sequences. 5. A pharmaceutical composition, comprising as active ingredient a protein comprising one of the following sequences: SEQ ID NO: 522 or SEQ ID NO: 524 and a pharmaceutically acceptable vehicle. 6. A combination product comprising mutated netrin 4 as set forth in SEQ ID NO: 522 or SEQ ID NO: 524, in combination with an anti-angiogenic agent AVASTIN (bevacizumab), MACUGEN (pegaptanib) and LUCENTIS (ranibizumab), or any other anti-VEGF agent. 7. A pharmaceutical composition comprising as active ingredient the nucleic acid of claim 2 and a pharmaceutically acceptable vehicle.

Details for Patent 7,999,072

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2024-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2024-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2024-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2024-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2024-11-22